Krasovec M, Elsner P, Burg G
Department of Dermatology, University Hospital Zurich, Switzerland.
Dermatology. 1993;186(4):248-52. doi: 10.1159/000247363.
We report on 3 patients who developed a generalized eczematous skin rash under treatment with simvastatin and pravastatin for hypercholesterolemia. These drugs are 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors and suppress cholesterol synthesis in the liver. Based on experimental data from the literature that showed eczematous changes in mice treated topically with the HMG-CoA reductase inhibitor lovastatin, we suspect that the rash observed in our patients may be a consequence of skin barrier dysfunction following inhibition of cholesterol biosynthesis.
我们报告了3例在使用辛伐他汀和普伐他汀治疗高胆固醇血症过程中出现全身性湿疹样皮疹的患者。这些药物是3-羟基-3-甲基戊二酰辅酶A（HMG-CoA）还原酶抑制剂，可抑制肝脏中的胆固醇合成。根据文献中的实验数据，局部应用HMG-CoA还原酶抑制剂洛伐他汀治疗的小鼠出现了湿疹样变化，我们怀疑在我们的患者中观察到的皮疹可能是胆固醇生物合成受到抑制后皮肤屏障功能障碍的结果。
